Pembrolizumab before surgery for high-risk melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can help people with high-risk melanoma. It is for patients whose melanoma has not spread and who have not had prior treatment for melanoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your melanoma must be high-risk (certain stages like pT3b-4b, or pT1b-3a with a high-risk Merlin test).
- You must be able to have a sentinel lymph node biopsy.
- You must not have any signs that the cancer has spread (based on scans and exams).
- You must not have had any prior treatment for melanoma (like immunotherapy or other drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving pembrolizumab (Keytruda) before surgery helps people with a certain type of advanced melanoma (stage IIb/c). The goal is to see if this treatment can improve outcomes before the tumor is removed.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests whether giving a combination of three immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. It is for people whose melanoma can be surgically removed, and the goal is to see if this approach is safe and effective.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. The drugs are given to boost your immune system to attack the cancer before it's removed.
This trial tests immunotherapy given before surgery to help shrink or control stage III melanoma that has spread to nearby areas (lymph nodes/region). If it works, it may improve outcomes after the melanoma is removed.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.